Guzman-Soto and colleagues (2016) noted that recent findings have shown that GnRH administration in an animal model of multiple sclerosis (experimental autoimmune encephalomyelitis, EAE) improves clinical signs of locomotion. These researchers examined if the administration of the synthetic analog of GnRH, leuprolide acetate (LA) -- besides its effects on clinical signs of locomotion -- also has an effect on the activation/expression levels of molecular markers of EAE, namely transcription nuclear factor (NF)-κB and the pro-inflammatory cytokines IL-1β, IL-17A, IL-23 and TNF-α. EAE spinal cords were collected from control and LA-administered rats. Lumbar sections were processed at 4 different time points during the course of the disease to analyze NF-κB activation by chemiluminescent Western blot, and during the EAE recovery phase to evaluate pro-inflammatory cytokine levels by quantitative real-time PCR. It was found that LA administration to EAE rats promoted a significant reduction of NF-κB activation during the course of the disease and also decreased the mRNA expression levels of the pro-inflammatory cytokines IL-1β, IL-17A and TNF-α in the EAE recovery phase; both effects were consistent with the decrease in the severity of clinical signs of locomotion induced by the treatment. The authors concluded that LA caused a reduction in the severity of locomotor activity, as well as in the activation of NF-κB and the number of pro-inflammatory markers in rats with EAE. They stated that these findings suggested the use of this agonist as a potential therapeutic approach for multiple sclerosis.
Dihydrotestosterone (DHT) (referred to as androstanolone or stanolone when used medically) can also be used in place of testosterone as an androgen. The availability of DHT is limited; it is not available in the United States or Canada, for instance, but it is available in certain European countries, including the United Kingdom , France , Spain , Belgium , Italy , and Luxembourg .  DHT is available in formulations including topical gel, buccal or sublingual tablets, and as esters in oil for intramuscular injection.  Relative to testosterone, and similarly to many synthetic AAS, DHT has the potential advantages of not being locally potentiated in so-called androgenic tissues that express 5α-reductase (as DHT is already 5α-reduced) and of not being aromatized into an estrogen (it is not a substrate for aromatase).
Kisspeptin plays a role in tumor suppression. In a study where malignant tumor cells were injected into a model system , the system was then tested for genes involved in the injected chromosome 6. KISS1 was discovered to be the only gene expressed in non-metastatic cells and absent in metastatic, metastatic meaning the ability for cancer to spread to unconnected areas. This suggested that there Kisspeptin is an essential regulation factor in whether or not a cell will be metastatic or not. Additional experimentation identified CRSP3 as the exact gene responsible for KISS1 regulation within chromosome 6. In clinical evidence studies, KISS1 and Kisspeptin were found in primary, metastatic tumors, and growing tumors showing decreased levels of KISS1 and Kisspeptin.  In conclusion, kisspeptin plays a large role in tumor suppression . When it is active in cells the tumor stays consolidated and does not spread or grow.